A retrospective study by Lawrentschuk et al. reviewed the records of PCa patients who were treated with a GnRH agonist (leuprorelin or goserelin) but underwent disease progression and were then rechallenged with the other GnRH agonist (goserelin or leuprorelin). The gene discussed is GNRH1; the disease is posterior cortical atrophy.